1. Functional analysis of SRY variants in individuals with 46,XY differences of sex development.
- Author
-
Idris FP, van den Bergen J, Robevska G, Ferreira LGA, Ferreira KR, Kizys MML, Dias da Silva MR, Bruggenwirth HT, van Bever Y, Sinclair AH, and Ayers KL
- Subjects
- Humans, Male, SOX9 Transcription Factor genetics, SOX9 Transcription Factor metabolism, Female, Sexual Development genetics, Disorder of Sex Development, 46,XY genetics, Gonadal Dysgenesis, 46,XY genetics, Sex-Determining Region Y Protein genetics, Sex-Determining Region Y Protein metabolism
- Abstract
In mammals, male sexual development is initiated by the expression of the Sex-determining-Region-Y (SRY) gene. SRY contains a highly conserved high mobility group (HMG) box essential for DNA binding and activity. Variants in SRY cause Differences of Sex Development (DSD), accounting for 10-15% of 46, XY gonadal dysgenesis cases. Here, we present the functional analysis of five SRY coding variants identified in patients with 46, XY DSD. Four variants (p.Asp58Glu, p.Arg75Lys, p.Met85Thr, and p.Arg86Ter) are located within the HMG box and one variant (p.Tyr198Cysfs∗18) located in the C-terminal domain. We functionally characterise the impact of these variants in vitro, investigating SRY localisation and transactivational activity using SOX9 regulatory elements that are responsive to SRY. We find that three variants (p.Met85Thr, p.Arg86Ter, and p.Tyr198Cysfs∗18) have reduced or abolished transactivational activity suggesting these are pathogenic, with the p.Arg86Ter variant undetectable in our assays and the p.Met85Thr variant exhibiting reduced nuclear localisation. The pathogenic mechanisms underlying reduced activity of the novel elongated p.Tyr198Cysfs∗18 variant is however unclear, although this variant also affected localisation. In contrast, two additional variants (p.Asp58Glu and p.Arg75Lys) had no discernible effects on nuclear localisation or transactivational activity despite in silico analysis predicting impaired DNA binding. Taken together, our data establish the likely pathogenicity of these SRY variants and improve diagnostic certainty for the patients in which they were identified., Competing Interests: Declaration of competing interest The authors have nothing to declare., (Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF